Biomedical subjects

H C Lin

Publications and source records attributed to H C Lin.

436 records · Page 25Linked to original sources

PubMedDate not supplied

Hemodynamic effects of acute tetrandrine and terlipressin administration on portal hypertensive rats.

The purpose of this study was to investigate the therapeutic effects of tetrandrine and terlipressin, alone or in combination, on anesthetized portal hypertensive rats. Portal hypertension was induced by partial portal vein ligation in Sprague-Dawley rats. Each portal hypertensive rat received one of three regimens: vehicle plus terlipressin, tetrandrine (.50 mg.kg-1.min-1) [corrected] plus terlipressin, or tetrandrine (.75 mg.kg-1.min-1) [corrected] plus terlipressin. Terlipressin dosage was 0.025 mg.kg-1.min-1 [corrected] infused for 3 min. Infusion of vehicle followed by terlipressin induced significant reduction of portal venous pressure (PVP, -24.3 +/- 1.5%) and prominent elevation of mean arterial pressure (MAP, 73.3 +/- 4.6%) as well as total peripheral resistance (TPR, 133 +/- 8%) from baseline, and there was a cardiodepressant response (cardiac index, CI, -30.6 +/- 3.8%; heart rate, HR, -10.4 +/- 2.1%). Infusion of tetrandrine (.50 mg.kg-1.min-1) [corrected] induced significant reduction of PVP (-7.2 +/- 0.9%), MAP (-12.5 +/- 1.6%), and TPR (-14.3 +/- 4.2%) from baseline. Infusions of tetrandrine followed by terlipressin induced significant reduction of PVP (-14.2 +/- 2.4%) but an increase in MAP (22.6 +/- 2.7%) and TPR (71.1 +/- 10.5%). Infusion of tetrandrine (.75 mg.kg-1.min-1) [corrected] induced significant reduction of PVP (-9.9 +/- 0.8%). MAP (-19.2 +/- 2.1%), and TPR (-24.1 +/- 2.1%) from baseline. Infusions of tetrandrine followed by terlipressin induced significant reduction of PVP (-14.0 +/- 1.1%) but an increase in MAP (14.0 +/- 2.7%) and TPR (75.2 +/- 5.2%). Compared with vehicle followed by terlipressin, tetrandrine significantly attenuated systemic pressor (MAP and TPR elevation), cardiodepressant (CI reduction) as well as portal hypotensive (PVP reduction) effects of terlipressin. Our results suggest that tetrandrine and terlipressin, alone or in combination, induced portal hypotensive effects in portal hypertensive rats. Combined tetrandrine and terlipressin administration ameliorated systemic pressor and cardiodepressant effects of terlipressin, but it also attenuated the latter's portal hypotensive effects.

Alkaloids↗

PubMedDate not supplied

Strokes in children: a medical center-based study.

Stroke is an important cause of mortality and morbidity in children. Cases of pediatric stroke admitted to National Taiwan University Hospital from January 1985 to December 1995 were reviewed. Patients whose stroke was obviously caused by premature birth, birth trauma or head injury were excluded. Totally 65 patients were enrolled, including 37 boys and 28 girls. Their ages ranged from birth to 18 years old. They were classified into two groups: ischemic stroke (38 patients) and hemorrhagic stroke (27 patients), according to the pathogenesis. The ages of onset, clinical manifestation, underlying diseases and treatment of these two groups were systematically analyzed. The major presenting symptoms of both ischemic and hemorrhagic strokes were motor deficit (65.8%) and consciousness disturbance (55.6%). A wide variety of diseases predisposing to strokes was identified. The major causes of hemorrhagic stroke were vascular malformation and oncologic conditions, with the latter, the most frequently encountered underlying diseases associated with childhood ischemic stroke. The mortality rate for hemorrhagic stroke was 37% and, for ischemic stroke, 21.1%. There was male predominance in pediatric stroke. Although the clinical symptoms and signs might provide some guidelines to differentiate between hemorrhagic and ischemic strokes, neuroimaging studies were crucial to more exact diagnosis. A variety of diseases may contribute to pediatric stroke. Early diagnosis determine treatability, then aggressive treatment are important.

Adolescent↗

PubMedDate not supplied

Transplantation for adrenoleukodystrophy with HLA-A and B nonidentical paternal marrow: report of one case.

We report the result of allogeneic bone marrow transplantation (BMT) in a 14-year-old boy who was neurologically severely involved with the childhood form of adrenoleukodystrophy (ALD) and received marrow from his HLA-A and B nonidentical, MLC-nonreactive paternal donor without T-cell depletion processing. Bone marrow transplantation corrected the excess content of very long chain fatty acid in plasma but did not arrest the deterioration of the neurological status during 3.5-year post-transplant follow-up period. Since partially matched or unrelated donors have been applied to clinical BMT successfully with current new techniques, ALD patients will have a better prognosis when they are transplanted in status of mild and early involvement. Our first experience may be helpful in more trials of BMT for genetic leukodystrophy in Taiwan.

Adolescent↗

PubMedDate not supplied

Effect of erythromycin on feeding intolerance in very low birth weight infants: a preliminary observation.

To investigate the effect of erythromycin on feeding intolerance in very low birth weight infants, from February 1997 to December 1997 twenty infants weighing less than 1500 g, with prolonged intolerance of enteral feeding, were enrolled in this study. The protocol for erythromycin treatment was: a loading dose of 30 mg/kg/day, divided into three portions given every eight hours intravenously for 1 hour over a three day period; then a maintenance dose of 3-5 mg/kg intravenously for one hour once a day was given until full feeding was well established. The assessment of erythromycin effect was the daily net orogastric balance (volume of orogastric tube feeding minus volume of orogastric aspirates). The mean gestational age was 27.1 +/- 2.0 weeks (mean +/- SD) and the mean birth weight was 1025 +/- 196 g. The mean age when erythromycin started was 19.5 +/- 14 days; the mean days after the initiation of erythromycin when orogastric tube feeding could be started and full feeding established were 2.4 +/- 1.1 days and 15.1 +/- 2.2 days, respectively. At the beginning of erythromycin treatment, the net balance of tube aspirates was -4.8 +/- 4.1 ml. The net balance rose significantly to 30.6 +/- 15.3 ml, 92.6 +/- 25.4 ml and 125.3 +/- 18.1 ml at 7, 14 and 21 days after erythromycin treatment, respectively. In conclusion, erythromycin treatment is a safe method to improve intolerance of enteral feeding in very low birth weight infants. It is suggested that the effect of erythromycin on gastrointestinal motility in these infants should be further investigated in the context of a randomized, controlled trial before widespread clinical implementation of this treatment.

Anti-Bacterial Agents↗